肺癌治療市場－全球產業規模、佔有率、趨勢、機會和預測，按癌細胞類型（非小細胞肺癌、小細胞肺癌）、按治療方法、按地區和競爭細分，2020 年至 2030 年

2024 年全球肺癌治療市場價值為 254.3 億美元，預計到 2030 年將達到 405.5 億美元，預測期內的複合年成長率為 9.62%。由於人們認知的提高、早期診斷以及標靶療法和免疫療法的進步，全球肺癌治療市場正在強勁成長。肺癌仍然是全球最常見和最致命的癌症之一，因此有效治療成為醫療保健系統的首要任務。吸菸率上升、環境污染物暴露和人口老化是推動創新治療方案需求的關鍵促進因素。非小細胞肺癌是最常見的類型，且治療進展最為顯著，尤其是透過針對基因突變的標靶療法。免疫療法也正在獲得發展勢頭，透過幫助人體免疫系統更有效地識別和攻擊癌細胞，為患者帶來了希望。這些治療方式正在重塑市場格局並提高患者的存活率。例如，世界衛生組織（WHO）認為菸草是重大健康風險，每年造成超過800萬人死亡，尤其是中低收入國家。 WHO支持採取無菸政策、廣告限制和增稅等行動，以遏止菸草使用並鼓勵戒菸。

關鍵市場促進因素

肺癌發生率上升

主要市場挑戰

治療費用高昂

主要市場趨勢

轉向個人化醫療

目錄

第1章：服務概述

• 市場定義
• 市場範圍
  • 覆蓋市場
  • 考慮學習的年限
  • 主要市場區隔

第2章：研究方法

第3章：執行摘要

第4章：顧客之聲

第5章：全球肺癌治療市場展望

• 市場規模和預測
  • 按價值
• 市場佔有率和預測
  • 依癌細胞類型（非小細胞肺癌 (NSCLC)、小細胞肺癌 (SCLC)）
  • 依治療方法（化療、放射治療、免疫治療、標靶治療、其他治療）
  • 按地區
  • 按公司分類（2022 年）
• 市場地圖
  • 依癌細胞類型
  • 按治療

第6章：北美肺癌治療市場展望

• 市場規模和預測
• 市場佔有率和預測
• 北美：國家分析
  • 美國
  • 加拿大
  • 墨西哥

第7章：歐洲肺癌治療市場展望

• 市場規模和預測
• 市場佔有率和預測
• 歐洲：國家分析
  • 法國
  • 德國
  • 英國
  • 義大利
  • 西班牙

第8章：亞太地區肺癌治療市場展望

• 市場規模和預測
• 市場佔有率和預測
• 亞太地區：國家分析
  • 中國
  • 日本
  • 印度
  • 韓國
  • 澳洲

第9章：南美洲肺癌治療市場展望

• 市場規模和預測
• 市場佔有率和預測
• 南美洲：國家分析
  • 巴西
  • 阿根廷
  • 哥倫比亞

第10章：中東和非洲肺癌治療市場展望

• 市場規模和預測
• 市場佔有率和預測
• MEA：國家分析
  • 阿拉伯聯合大公國
  • 沙烏地阿拉伯
  • 南非

第 11 章：市場動態

• 驅動程式
  • 肺癌盛行率不斷上升。
  • 吸煙者數量增加
  • 免疫療法需求上升
• 挑戰
  • 癌症治療費用高昂
  • 藥物的副作用
  • 缺乏熟練勞動力

第 12 章：市場趨勢與發展

• 產品發布
• 併購
• 技術進步

第 13 章：臨床試驗分析

第 14 章：全球肺癌治療市場：SWOT 分析

第 15 章：競爭格局

• AstraZeneca Plc
• Boehringer Ingelheim International GmbH.
• Bristol-Myers Squibb Company
• Eli Lilly and Company
• F. Hoffmann-La Roche Ltd.
• Merck & Co
• Pfizer Inc.
• Allergan Inc.
• Teva Pharmaceutical Industries Ltd.
• Abbvie, Inc.

第 16 章：策略建議

第17章調查會社について,免責事項

Global Lung Cancer Therapeutics Market was valued at USD 25.43 billion in 2024 and is expected to reach USD 40.55 billion by 2030 with a CAGR of 9.62% during the forecast period. The global lung cancer therapeutics market is witnessing robust growth due to increasing awareness, early diagnosis, and advancements in targeted and immunotherapies. Lung cancer remains one of the most commonly diagnosed and deadliest forms of cancer worldwide, making effective treatment a high priority for healthcare systems. The rising prevalence of smoking, exposure to environmental pollutants, and aging populations are key drivers fueling demand for innovative treatment options. Non-small cell lung cancer is the most prevalent type and has seen the greatest therapeutic advancements, especially through targeted therapies that focus on genetic mutations. Immunotherapies are also gaining momentum, offering hope by helping the body's immune system recognize and attack cancer cells more effectively. These treatment modalities are reshaping the market landscape and improving patient survival rates. For instance, The World Health Organization (WHO) recognizes tobacco as a significant health risk, causing over 8 million deaths each year, especially in low- and middle-income countries. WHO supports actions like smoke-free policies, advertising restrictions, and tax increases to curb tobacco use and encourage smoking cessation.

Key Market Drivers

Rising Incidence of Lung Cancer

The rising incidence of lung cancer is one of the most significant drivers propelling the global lung cancer therapeutics market. For instance, the growing prevalence of various cancer types, with lung cancer being one of the most common, has led to an increasing demand for lung cancer therapeutics. Rising incidences of lung cancer across all demographics and age groups contribute to this demand. The American Cancer Society (ACS) reports that approximately 13% of all new cancer diagnoses are lung cancers. Lung cancer continues to be one of the most frequently diagnosed cancers worldwide and remains a leading cause of cancer-related deaths. This growing burden is closely linked to widespread tobacco use, which remains the most common risk factor, particularly in low- and middle-income countries where smoking rates are still high. The exposure to secondhand smoke, environmental pollutants, occupational carcinogens like asbestos, and increasing levels of urban air pollution have contributed to a broader and more diverse at-risk population.

The surge in lung cancer cases has heightened the need for timely diagnosis and effective treatment, prompting healthcare systems to invest more in therapeutics. This has led to significant market expansion, particularly in areas focused on advanced treatments like targeted therapies and immunotherapies. As more patients are diagnosed at earlier stages due to improved screening programs and public awareness initiatives, the opportunity for therapeutic intervention increases, further driving demand for innovative drug development.

The changing lifestyle patterns, increasing life expectancy, and a growing elderly population are contributing to a higher number of lung cancer diagnoses globally. The disease's high mortality rate has also intensified efforts from pharmaceutical companies and research organizations to accelerate clinical trials and regulatory approvals for novel therapies. The global response to this growing health crisis is reflected in rising healthcare expenditures and policy reforms aimed at improving cancer care access.

Key Market Challenges

High Treatment Costs

High treatment costs are one of the most significant challenges facing the global lung cancer therapeutics market. While advancements in targeted therapies and immunotherapies have revolutionized the treatment landscape, these therapies come with high price tags. For instance, newer treatments that target specific genetic mutations, such as EGFR inhibitors or immune checkpoint inhibitors, can cost patients tens of thousands of dollars per year. This makes them financially inaccessible for a large portion of the global patient population, especially in low- and middle-income countries where healthcare systems may already be strained.

The high cost of these treatments is often a barrier for patients who do not have sufficient insurance coverage or financial support. In many regions, the lack of universal healthcare coverage means that out-of-pocket expenses for patients are significant. This situation can lead to delayed treatment or even treatment abandonment, resulting in poorer outcomes.For those who do access these therapies, long-term costs can be unsustainable, as many lung cancer therapies require continuous use.

Pharmaceutical companies argue that the high costs are necessary to recoup the considerable investments made in research, development, and clinical trials. However, the pricing of cancer therapies has sparked widespread debate, with calls for more affordable pricing models or reimbursement strategies to ensure equitable access to these life-saving treatments.

Ultimately, the high treatment costs create a divide between those who can afford cutting-edge therapies and those who cannot, limiting the global reach of these innovative treatments and hindering efforts to reduce lung cancer mortality rates worldwide.

Key Market Trends

Shift Toward Personalized Medicine

The shift toward personalized medicine is one of the most significant trends in the global lung cancer therapeutics market, marking a transformative approach to treatment that aims to tailor therapies to individual patients based on their genetic, molecular, and environmental profiles. This paradigm shift is reshaping how lung cancer is diagnosed, treated, and managed, moving away from a one-size-fits-all approach to more targeted, effective, and less invasive therapies.

Personalized medicine in lung cancer relies heavily on identifying specific genetic mutations, biomarkers, and molecular characteristics of both the cancer cells and the patient. For example, targeted therapies are now developed to treat non-small cell lung cancer (NSCLC) based on mutations such as EGFR, ALK, ROS1, and BRAF. These therapies can directly target the molecular drivers of cancer growth, resulting in more effective treatments with fewer side effects than traditional chemotherapy. The success of targeted therapies in improving survival rates has demonstrated the value of personalized approaches and increased demand for genetic testing and biomarkers.

The growing field of immunotherapy, especially immune checkpoint inhibitors, has benefited from the personalized medicine trend. These therapies are often more effective in certain patients based on the expression of biomarkers like PD-L1. By identifying which patients are most likely to benefit from immunotherapy, healthcare providers can optimize treatment plans and avoid unnecessary therapies for those less likely to respond.

The expansion of personalized medicine has also spurred growth in companion diagnostics, which are essential for identifying the right patient populations for specific treatments. The availability of such diagnostics helps ensure that patients receive the most appropriate therapies based on their individual profiles, leading to better outcomes and a more efficient use of healthcare resources.

The shift toward personalized medicine is driving significant innovation in the lung cancer therapeutics market, making treatments more precise, effective, and patient-centered. As research advances, the integration of personalized approaches is expected to continue expanding, further improving survival rates and quality of life for lung cancer patients.

Key Market Players

• AstraZeneca Plc
• Boehringer Ingelheim International GmbH.
• Bristol-Myers Squibb Company
• Eli Lilly and Company
• F. Hoffmann-La Roche Ltd.
• Merck & Co
• Pfizer Inc.
• Allergan Inc.
• Teva Pharmaceutical Industries Ltd.
• Abbvie, Inc.

Report Scope:

In this report, the Global Lung Cancer Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Lung Cancer Therapeutics Market, By Cancer Cell Type:

• Non-small Cell Lung Cancer (NSCLC)
• Small Cell Lung Cancer (SCLC)

Lung Cancer Therapeutics Market, By Treatment:

• Chemotherapy
• Radiation Therapy
• Immunotherapy
• Targeted Therapy
• Other Treatments

Lung Cancer Therapeutics Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Lung Cancer Therapeutics Market.

Available Customizations:

Global Lung Cancer Therapeutics Market report with the given market data, TechSci Research, offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Service Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, and Trends

4. Voice of Customer

5. Global Lung Cancer Therapeutics Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Cancer Cell Type (Non-small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC))
  • 5.2.2. By Treatment (Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapy, Other Treatments)
  • 5.2.3. By Region
  • 5.2.4. By Company (2022)
• 5.3. Market Map
  • 5.3.1. By Cancer Cell Type
  • 5.3.2. By Treatment

6. North America Lung Cancer Therapeutics Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Cancer Cell Type (Non-small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC)
  • 6.2.2. By Treatment (Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapy, Other Treatments)
  • 6.2.3. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Lung Cancer Therapeutics Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Cancer Cell Type
      • 6.3.1.2.2. By Treatment
  • 6.3.2. Canada Lung Cancer Therapeutics Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Cancer Cell Type
      • 6.3.2.2.2. By Treatment
  • 6.3.3. Mexico Lung Cancer Therapeutics Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Cancer Cell Type
      • 6.3.3.2.2. By Treatment

7. Europe Lung Cancer Therapeutics Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Cancer Cell Type (Non-small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC)
  • 7.2.2. By Treatment ( Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapy, Other Treatments)
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Lung Cancer Therapeutics Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Cancer Cell Type
      • 7.3.1.2.2. By Treatment
  • 7.3.2. Germany Lung Cancer Therapeutics Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Cancer Cell Type
      • 7.3.2.2.2. By Treatment
  • 7.3.3. United Kingdom Lung Cancer Therapeutics Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Cancer Cell Type
      • 7.3.3.2.2. By Treatment
  • 7.3.4. Italy Lung Cancer Therapeutics Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Cancer Cell Type
      • 7.3.4.2.2. By Treatment
  • 7.3.5. Spain Lung Cancer Therapeutics Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Cancer Cell Type
      • 7.3.5.2.2. By Treatment

8. Asia-Pacific Lung Cancer Therapeutics Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Cancer Cell Type (Non-small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC)
  • 8.2.2. By Treatment ( Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapy, Other Treatments)
  • 8.2.3. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Lung Cancer Therapeutics Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Cancer Cell Type
      • 8.3.1.2.2. By Treatment
  • 8.3.2. Japan Lung Cancer Therapeutics Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Cancer Cell Type
      • 8.3.2.2.2. By Treatment
  • 8.3.3. India Lung Cancer Therapeutics Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Cancer Cell Type
      • 8.3.3.2.2. By Treatment
  • 8.3.4. South Korea Lung Cancer Therapeutics Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Cancer Cell Type
      • 8.3.4.2.2. By Treatment
  • 8.3.5. Australia Lung Cancer Therapeutics Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Cancer Cell Type
      • 8.3.5.2.2. By Treatment

9. South America Lung Cancer Therapeutics Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Cancer Cell Type (Non-small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC)
  • 9.2.2. By Treatment ( Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapy, Other Treatments)
  • 9.2.3. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Lung Cancer Therapeutics Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Cancer Cell Type
      • 9.3.1.2.2. By Treatment
  • 9.3.2. Argentina Lung Cancer Therapeutics Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Cancer Cell Type
      • 9.3.2.2.2. By Treatment
  • 9.3.3. Colombia Lung Cancer Therapeutics Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Cancer Cell Type
      • 9.3.3.2.2. By Treatment

10. Middle East and Africa Lung Cancer Therapeutics Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Cancer Cell Type (Non-small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC)
  • 10.2.2. By Treatment (Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapy, Other Treatments)
  • 10.2.3. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. UAE Lung Cancer Therapeutics Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Cancer Cell Type
      • 10.3.1.2.2. By Treatment
  • 10.3.2. Saudi Arabia Lung Cancer Therapeutics Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Cancer Cell Type
      • 10.3.2.2.2. By Treatment
  • 10.3.3. South Africa Lung Cancer Therapeutics Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Cancer Cell Type
      • 10.3.3.2.2. By Treatment

11. Market Dynamics

• 11.1. Drivers
  • 11.1.1. Increasing Prevalence of Lung Cancer.
  • 11.1.2. Rise in the number of Tobacco Smokers
  • 11.1.3. Rise in demand for Immunotherapy
• 11.2. Challenges
  • 11.2.1. High Cost of Cancer Treatment
  • 11.2.2. Side Effects of Drugs
  • 11.2.3. Lack of skilled workforce

12. Market Trends & Developments

• 12.1. Product Launches
• 12.2. Mergers & Acquisitions
• 12.3. Technological Advancements

13. Clinical Trial Analysis

14. Global Lung Cancer Therapeutics Market: SWOT Analysis

15. Competitive Landscape

• 15.1. AstraZeneca Plc
• 15.2. Boehringer Ingelheim International GmbH.
• 15.3. Bristol-Myers Squibb Company
• 15.4. Eli Lilly and Company
• 15.5. F. Hoffmann-La Roche Ltd.
• 15.6. Merck & Co
• 15.7. Pfizer Inc.
• 15.8. Allergan Inc.
• 15.9. Teva Pharmaceutical Industries Ltd.
• 15.10. Abbvie, Inc.

16. Strategic Recommendations

17. About Us & Disclaimer